NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee B meeting minutes

**Minutes:** Unconfirmed

**Date:** Thursday 13th June 2024

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Charles Crawley (Chair) Present for all items
2. Anna Pracz Present for all items
3. Baljit Singh (Vice-chair) Present for all items
4. Dr Bushra Hasnie Present for all items
5. Dr Daniel Gallacher Present for all items
6. Dr Mark Tanner Present for all items
7. Dr Natalia Kunst Present for all items
8. Dr Rhiannon Owen Present for all items
9. Dr Toby Smith Present for all items
10. Dr Veline L’Esperance Present for all items
11. Gabriel Rogers  Present for all items
12. Lisa Attrill Present for all items
13. Nigel Westwood Present for all items
14. Peter Wheatley-Price Items 1.1 to 4.2.2
15. Professor David McAllister Present for all items
16. Tony Wootton Present for all items
17. Vanessa Danielson Present for all items

NICE staff (key players) present

Emily Crowe, Associate Director Present for all items

Jeremy Powell, Project Manager Items 1.1 to 4.2.2

Eleanor Donegan, Heath Technology Assessment Adviser Items 1.1 to 4.2.2

Thomas Palmer, Heath Technology Assessment Analyst Items 1.1 to 4.2.2

Leena Issa, Project Manager Items 5.1 to 5.2.2

Nigel Gumbleton, Heath Technology Assessment Adviser Items 5.1 to 5.2.2

Harsimran Sarpal, Heath Technology Assessment Analyst Items 5.1 to 5.2.2

External assessment group representatives present

Geoff Frampton, Southampton Health Technology Assessments Centre (SHTAC), University of Southampton Items 1.1 to 4.1.3

Neelam Kalita, Southampton Health Technology Assessments Centre (SHTAC), University of Southampton Items 1.1 to 4.1.3

Jonathan Shepherd, Southampton Health Technology Assessments Centre (SHTAC), University of Southampton Items 5.1 to xx

Joanne Lord, Southampton Health Technology Assessments Centre (SHTAC), University of Southampton Items 5.1 to xx

Clinical, Patient & NHS England experts present

Abuk Mabil, Patient expert, nominated by Muscular Dystrophy UK

 Items 1.1 to 4.1.3

Gary Mahon, Patient expert, nominated by Muscular Dystrophy UK

 Items 1.1 to 4.1.3

Channa Hewamadduma, Consultant Neuromuscular Neurologist, Clinical expert nominated by Myaware Items 1.1 to 4.1.3

Maria Isabel Da Silva Leite, Consultant Neurologist, Clinical expert nominated by UCB

 Items 1.1 to 4.1.3

Jonathan Aning, Clinical expert, nominated by British Association of Urological Surgeons (BAUS) Items 5.1 to xx

Amarnath Challapalli, Clinical expert, nominated by British Uro-Oncology Group (BUG)

 Items 5.1 to 5.1.3

Stephen Allen, Patient expert, nominated by Tackle Prostate Cancer

 Items 5.1 to 5.1.3

Peter Rose, Patient expert, nominated by Prostate Cancer UK

 Items 5.1 to 5.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Warren Linley, Alistair Patton, Andrew Makin. Stuart Williams, Francis Drobniewski and Hatim Abdulhussein.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Wednesday 15th May.
1. **Appraisal of Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]**
	1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from UCB Pharma.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11096).
		3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by David McAllister (clinical) Peter Wheatley-Price (cost) and Nigel Westwood (lay).
	2. Part 2 –Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11096>.
1. **Appraisal of Relugolix for treating hormone-sensitive prostate cancer [ID6187]**
	1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Accord Healthcare Limited.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11141).
		3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Tony Wootton (lay), Lisa Attrill (cost) and Natalia Kunst (clinical).
		4. The committee discussed confidential information submitted for this item.
	2. Part 2 – Closed session (company representatives, patient and clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11141>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee B will be held on Thursday 11th July 2024 and will start promptly at 9am.